News
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...
U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.
Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.
Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...
CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...
Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...
CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...
BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...
The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...
Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results